Search Results - "Vocila, Linda"

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer by Pierobon, Mariaelena, Ramos, Corinne, Wong, Shukmei, Hodge, K Alex, Aldrich, Jessica, Byron, Sara, Anthony, Stephen P, Robert, Nicholas J, Northfelt, Donald W, Jahanzeb, Mohammad, Vocila, Linda, Wulfkuhle, Julia, Gambara, Guido, Gallagher, Rosa I, Dunetz, Bryant, Hoke, Nicholas, Dong, Ting, Craig, David W, Cristofanilli, Massimo, Leyland-Jones, Brian, Liotta, Lance A, O'Shaughnessy, Joyce A, Carpten, John D, Petricoin, Emanuel F

“…Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling,…”
Get full text

Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial by Pierobon, Mariaelena, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad, Wong, Shukmei, Hodge, Kimberly A., Baldelli, Elisa, Aldrich, Jessica, Craig, David W., Liotta, Lance A., Avramovic, Sanja, Wojtusiak, Janusz, Alemi, Farrokh, Wulfkuhle, Julia D., Bellos, Angela, Gallagher, Rosa I., Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David M., Vocila, Linda, Dunetz, Bryant, Carpten, John D., Petricoin, Emanuel F., Anthony, Stephen P.

“…This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi‐omic molecular profiling (MoMP)…”
Get full text

Abstract 3129: PD-L1 expression differs across cancer metastatic sites from breast tumors by Pierobon, Mariaelena, Hodge, K Alex, Baldelli, Elisa, Anthony, Steven, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad J., Vocila, Linda, Liotta, Lance A., Dunetz, Bryant, Petricoin, Emanuel F.

“…Background: Although the efficacy of different immunotherapeutic agents varies greatly across tumor types, little is known about the role of different…”
Get full text

Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience by Pierobon, Mariaelena, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad, Wong, Shukmei, Hodge, K. Alex, Aldrich, Jessica, Craig, David W., Liotta, Lance A., Wulfkuhle, Julia Dianne, Gallagher, Rosa Isela, Arguello, David, Conrad, Amber, Kemkes, Ariane C., Loesch, David M., Vocila, Linda, Dunetz, Bryant, Carpten, John D., Petricoin, Emanuel, Anthony, Stephen Patrick

“…Abstract only…”
Get full text

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors by Galsky, Matthew D., Von Hoff, Daniel D., Neubauer, Marcus, Anderson, Thomas, Fleming, Mark, Nagarwala, Yasir, Mahoney, Janine M., Midwinter, Dawn, Vocila, Linda, Zaks, Tal Z.

“…Summary Background : To explore the activity of lapatinib with a novel trial design focused on the drug target rather than on histology. Methods : Patients…”
Get full text

Abstract P1-07-23: Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: Implications for patient stratification to targeted treatment by Pierobon, Mariaelena, Anthony, Stephen P, Reeder, K Alex, Robert, Nicholas J, Northfelt, Donald W, Jahanzeb, Mohammad, Vocila, Linda, Wulfkuhle, Julia D, Dunetz, Bryant, Liotta, Lance A, Petricoin, Emanuel F

“…Background: The development of distant metastases is the strongest prognostic factor associated with cancer mortality. Customization of treatment based on…”
Get full text

Abstract 2043: Protein pathway activation mapping analysis of metastatic breast cancer reveals potential new targets for personalized therapy by Pierobon, Mariaelena, Reeder, Kimberly A., Jameson, Gayle, Robert, Nicholas, Anthony, Stephen P., Sachdev, Jasgit, Vocila, Linda, Wulfkuhle, Julia, Baldelli, Elisa, Liotta, Lance, Petricoin, Emanuel F.

“…Introduction: It is well known that the development of distant metastasis is the strongest prognostic factor associated with cancer mortality. Recent genomic…”
Get full text

A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition by Northfelt, Donald W., Hamburg, Solomon I., Borad, Mitesh J., Seetharam, Mahesh, Curtis, Kelly Kevelin, Lee, Peter, Crowell, Brynne, Vocila, Linda, Fredlund, Paul, Gilbert, Mark J., Mast, Catherine Patricia, Semple, Sean C., Judge, Adam D., MacLachlan, Ian, Ramanathan, Ramesh K.

“…Abstract only TPS2621 Background: TKM-080301 is a lipid nanoparticle formulation of a small interfering RNA (siRNA) directed against PLK1, a serine/threonine…”
Get full text

A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer by Jameson, Gayle S., Petricoin, Emanuel, Sachdev, Jasgit C., Liotta, Lance A., Loesch, David, Anthony, Stephen Patrick, Chadha, Manpreet, Pierobon, Mariaelena, Reeder, Alex, Fulk, Monica, Vocila, Linda, Cantafio, Nina, Dunetz, Bryant, Robert, Nicholas J.

“…Abstract only TPS11123 Background: The objective of this prospective pilot study was to determine if treatment selected by molecular profiling (MP) of…”
Get full text

Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors by Ramanathan, Ramesh K., Hamburg, Solomon I., Borad, Mitesh J., Seetharam, Mahesh, Kundranda, Madappa N., Lee, Peter, Fredlund, Paul, Gilbert, Mark, Mast, Cathy, Semple, Sean C., Judge, Adam D., Crowell, Brynne, Vocila, Linda, MacLachlan, Ian, Northfelt, Donald W.

“…Background: Polo-like kinase 1 (PLK1) is a serine/threonine kinase that regulates multiple critical aspects of cell progression. PLK1 is over-expressed in many…”
Get full text

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics by Galsky, Matthew D., Zaks, Tal, Hassani, Habib, Vocila, Linda, Sonpavde, Guru, Hutson, Thomas E., Von Hoff, Daniel D.

“…Summary Purpose : To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than…”
Get full text